1Kostova I.Platinum complexes as anticancer agents [ J].Re- cent Patents an Anticancer Drug Discovery, 2006, 1: 1-22.
2Abu-Surrah A S, Kettunen M.Platinum group antitumor chemistry: Design and development of new anticancer drugs complementary to cisplatin [J].Curt Med Chem, 2006, 1 3 : 1337-1357.
3Altaha R, 1 .iang x, Yu J], et al. Excision repair cross com- plementing- group 1: gene expression and platinum resis- tance [ J]. Int J Mol Med, 2004, 14 (6) : 959-970.
4Wynne P, Newton C, Ledermann JA, etal. Enhanced repair of DNA interstrand crosslinking in ovarian cancer ceils from patients following treatment with platinum-based che- motherapy[J]. Br J Cancer,2007,97 (7):927-933.
5Fuenesa MA, Castillab J, Alonsoa C, et al. Cisplatin bio- chemical mechanism of action: from cytotoxieity to induc- tion of cell death through interconnections between apop- totic and necrotic pathways [J].CurtMed Chem, 2003, 10 (3) :257-266.
6Rabik CA, Dolan ME.Molecular mechanisms of resistance and toxicity associated with platinating agents [J].Cancer Treat Rev, 2007,33 ( 1 ) : 9-23.
7Martin LP.Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways [J].Clin Cancer Res, 2008,14(5) : 1291-1295.
8Oda S, Kuraoka I, Maehara Y. DNA repair as a determi- nant of tumour chemosensitivity [J].Gan To Kagaku Ryo- ho, 2007,34 (3) : 347-357.
9Matsubara J, Nishina T.Yamada Y, et al. Impacts of exci- sion repair cross- complementing gene 1 (ERCC1), dihy- dropyrimidine dehydrogenase, and epidermal growth fac- tor receptor on the outcomes of patients with advanced gastric cancer[J]. Br J Cancer,2008,98(4) :832-839.
10Costa RM, Chigancas V, Galhardo Rda S, et al. The eu] karyotic nucleotide excision repair pathway [J]. Biochiml ie,2003,85( 1 1 ) : 1083-1099. I.
2BRADBURY P A,MARSHALL A L,KULKE A H,et al.Prognostic significance of nuclear excision (NER) and base excision (BER) DNA repair gene polymorphisms in esophageal cancer[J].Clin Oncol:2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition),2007,25(18S):2511.
3RYU J S,HONG Y C,HAN H S,et al.Association between polymorphisms of ERCC1 and XPD and survival in non-small cell lung cancer patients treated with cisplatin combination chemotherapy[J].Lung Cancer,2004,44(3):311-316.
4KANG S,JU W,KIM J W,et al.Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer[J].Exp Mol Med,2006,38(3):320-324.
5KWON H C,ROH M S,OH S Y,et al.Prognostic value of expression of ERCC1,thymidylate synthase,and glutathione-S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer[J].Ann Oncol,2007,18(3):504-509.
6RUZZO A,GRAZIANO F,KAWAKAMI K,et al.Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy[J].J Clin Oncol,2006,24(12):1883-1891.
7SUN N,SUN X,CHEN B,et al.MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer[J].Cancer Chemother Pharmacol,2010,65(3):437-446.
8STOEHLMACHER J,PARK D J,ZHANG W,et al.Association between glutathione-S-transferase P1,T1,and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer[J].J Natl Cancer Inst,2002,94(12):936-942.
9GRAZIANO F,RUZZO A,LOUPAKIS F,et al.Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy[J].Br J Cancer,2008,99(5):716-721.
10DOTOR E,CUATRECASES M,MARTíNEZ-INIESTA M,et al.Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment[J].J Clin Oncol,2006,24(10):1603-1611.
1Jazich AR, Hussain M, Howington JA, et al. Prognostic factors in patients with surgically resected stages I and II non-small cell lung cancer[J]. Ann Thorac Surg, 2000,70 (4) : 1168-1171.
2Arriagada R, Bergman B, Dunant A, et al. Gisplatin-based adjuvant chemotherapy in patients with completely resec- ted non-small cell lung cancer[J]. N Engl J Med, 2004, 350(4) :351-360.
3Croteau DL, Peng Y, Van Houten B. DNA repair gets physical:mapping an XPA-binding site on ERCC1FJ]. DNA Repair (Amst) ,2008,7(5) :819-826.
4Bernstein C, Bernstein H, Payne CM, et al. DNA repair/ pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis [J].Murat Res,2002,511(2):145-151.
5Simon GR1, Sharma S, Cantor A, et al. ERCC1 expression is a predictor of survival in resected patients with non- small-cell lung cancer[J]. Chest, 2005,127 (3) : 978-983.
6Olaussen KA,Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung Cancer and cisplatin-based adjuvant chemotherapy[J]. N Engl J Med,2006,355(10) : 983-991.
7Rosell R, Taron M, Camps C, et al. Influence of genetic markers on survival in non small cell lung cancer [J]. Drugs Today(Barc),2003,39(10) :775 -786.
8Rosell R, Lord RV,Taron M, et al. DNA repair and cispl- atin resistance in non-small-cell lung cancer[J]. Lung Cancer,2002,38(3) :217-227.
9Chang IY, Kim MH, Kim HB, et al. Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin[J]. Biochem Biophys Res Commun,2005,327(1) :225 -233.
10Reed E,Dabholkar M,Thornton K, et al. Evidence for in the appearance of mRNAs of nucleotide excision repair genes in human ovarian cancer tissues[J]. Oncol Rep, 2007, (5) : 1123-1128.
